Pathology: mNSCLC - L1 - all population; mNSCLC - L1 - PDL1 negative; mNSCLC - L1 - PDL1 positive; non squamous - mNSCLC - L1 - all population; non squamous - mNSCLC - L1 - Wild Type (WT); squamous - mNSCLC - L1 - all population;
mNSCLC - L1 - all population | mNSCLC - L1 - PDL1 negative | mNSCLC - L1 - PDL1 positive | non squamous - mNSCLC - L1 - all population | non squamous - mNSCLC - L1 - Wild Type (WT) | squamous - mNSCLC - L1 - all population | |||||||||||||||||||||||
EMPOWER lung1 (all population), 2021 | MYSTIC (D ; all population), 2020 | ORIENT-11, 2020 | CheckMate 227 (NC vs C ; PDL1<1%), 2018 | IMpower-110 (TC2/3 or IC2/3), 2020 | IMpower-110 (TC3 or IC3), 2020 | IMpower-110 (TC1/2/3 or IC1/2/3), 2020 | EMPOWER lung1 (PDL1>50%), 2021 | MYSTIC (D ; PDL1>25%), 2020 | CheckMate 026 (PDL1>1%), 2016 | CheckMate 026 (PDL1>5%), 2016 | KEYNOTE-042 (PDL1>20%), 2019 | KEYNOTE-042 (PDL1>1%), 2019 | KEYNOTE-042 (PDL1>50%), 2019 | KEYNOTE-024 (PDL1>50%), 2016 | IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 | IMpower-130 (all population), 2019 | IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 | IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 | IMpower-150 (ABCP vs BPC WT), 2018 | IMpower-130 (WT), 2019 | IMpower-132 (WT), 0 | KEYNOTE-021, 2016 | KEYNOTE-189, 2018 | IMpower-131 (ACnP), 2020 | IMpower-131 (ACP) EXPLORATORY, 2020 | KEYNOTE-407, 2018 | ||
pembrolizumab alone | 4 | T1 | T1 | T1 | T1 | |||||||||||||||||||||||
atezolizumab alone | 3 | T1 | T1 | T1 | ||||||||||||||||||||||||
atezolizumab plus carboplatin plus nab-paclitaxel | 3 | T1T0 | T1 | T1 | ||||||||||||||||||||||||
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel | 3 | T1 | T1 | T1 | ||||||||||||||||||||||||
cemiplimab | 2 | T1 | T1 | |||||||||||||||||||||||||
durvalumab alone | 2 | T1 | T1 | |||||||||||||||||||||||||
atezolizumab plus carboplatin plus paclitaxel | 2 | T1 | T1 | |||||||||||||||||||||||||
pembrolizumab plus SoC | 2 | T1 | T1 | |||||||||||||||||||||||||
nivolumab alone | 2 | T1 | T1 | |||||||||||||||||||||||||
atezolizumab plus pemetrexed and platin | 1 | T1 | ||||||||||||||||||||||||||
sintillimab plus SoC | 1 | T1 | ||||||||||||||||||||||||||
nivolumab plus SoC | 1 | T1 | ||||||||||||||||||||||||||
pembrolizumab and pemetrexed plus platin | 1 | T1 | ||||||||||||||||||||||||||
nab-paclitaxel | 0 | T0 | ||||||||||||||||||||||||||
carboplatin plus nab-paclitaxel | 0 | T0 | T0 | |||||||||||||||||||||||||
placebo plus SoC | 0 | T0 | T0 | T0 | ||||||||||||||||||||||||
pemetrexed plus platin | 0 | T0 | T0 | T0 | ||||||||||||||||||||||||
bevacizumab plus carboplatin and paclitaxel | 0 | T0 | T0 | T0 | T0 | |||||||||||||||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 |